Π‘ΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΈΠΌΠΌΡΠ½ΠΎΠΌΠΎΠ΄ΡΠ»ΠΈΡΡΡΡΠ΅ΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠ°ΡΡΠ΅ΡΠ½Π½ΠΎΠ³ΠΎ ΡΠΊΠ»Π΅ΡΠΎΠ·Π°
ΠΠΈΡΡΠ΅ΡΡΠ°ΡΠΈΡ
Π Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ ΡΡΡΠ΅ΡΡΠ²ΡΠ΅Ρ ΠΎΠ±ΡΠ΅Π΅ ΠΌΠ½Π΅Π½ΠΈΠ΅ ΠΎ Π²Π΅Π΄ΡΡΠ΅ΠΉ ΡΠΎΠ»ΠΈ ΠΈΠΌΠΌΡΠ½Π½ΡΡ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠΎΠ² Π² ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π΅ PC (ΠΡΡΠ΅Π² Π.Π. Ρ ΡΠΎΠ°Π²Ρ., 1997; ΠΠ°Π²Π°Π»ΠΈΡΠΈΠ½ Π. Π., ΠΠ°Ρ Π°ΡΠΎΠ²Π° Π. Π., 2004; Hohlfeld R., 1997). ΠΠ΅ΡΠ²ΠΎΠ½Π°ΡΠ°Π»ΡΠ½Π°Ρ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΡ Π°Π½ΡΡΠ³ΠΈΡΠ½ΡΡ , Π½Π΅Π°ΠΊΡΠΈΠ²Π½ΡΡ CD4+ Π’-ΠΊΠ»Π΅ΡΠΎΠΊ ΠΏΡΠΎΠΈΡΡ ΠΎΠ΄ΠΈΡ Π²Π½Π΅ ΡΠ΅Π½ΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π½Π΅ΡΠ²Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ (Π¦ΠΠ‘). ΠΠ·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠ΅Π³ΠΎ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° Π’-ΠΊΠ»Π΅ΡΠΊΠΈ ΠΈ Π°ΡΡΠΎΠ°Π½ΡΠΈΠ³Π΅Π½Π°, ΡΠ²ΡΠ·Π°Π½Π½ΠΎΠ³ΠΎ Ρ ΠΌΠΎΠ»Π΅ΠΊΡΠ»Π°ΠΌΠΈ II ΠΊΠ»Π°ΡΡΠ°… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
- Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΡΠ΄Π΅ΡΠΆΠΊΠ°
- ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°
- ΠΡΡΠ³ΠΈΠ΅ ΡΠ°Π±ΠΎΡΡ
- ΠΠΎΠΌΠΎΡΡ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈ
Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΡΡΡΠ°Π½ΠΈΡΡ
- Π‘ΠΏΠΈΡΠΎΠΊ ΡΠΎΠΊΡΠ°ΡΠ΅Π½ΠΈΠΉ
- ΠΠ»Π°Π²Π° I. ΠΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- ΠΠ»Π°Π²Π° II. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ
- ΠΠ»Π°Π²Π° III. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ PC ΠΠΎΠΏΠ°ΠΊΡΠΎΠ½ΠΎΠΌ
- ΠΠ»Π°Π²Π° IV. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ PC ΠΠ΅ΡΠ°ΡΠ΅ΡΠΎΠ½ΠΎΠΌ
- ΠΠ»Π°Π²Π° V. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ PC Π Π΅Π±ΠΈΡΠΎΠΌ-22 ΠΌΠΊΠ³
- ΠΠ»Π°Π²Π° VI. Π‘ΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π»Π΅ΡΠ΅Π½ΠΈΡ, Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΈ ΠΏΡΠΈΠ²Π΅ΡΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΠΊ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΠΎΠΏΠ°ΠΊΡΠΎΠ½ΠΎΠΌ,
- ΠΠ΅ΡΠ°ΡΠ΅ΡΠΎΠ½ΠΎΠΌ ΠΈ Π Π΅Π±ΠΈΡΠΎΠΌ-22 ΠΌΠΊΠ³
- ΠΠ»Π°Π²Π° VII. ΠΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ²
- ΠΡΠ²ΠΎΠ΄Ρ
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- ΠΠ»Π°Π΅Π² Π.Π. ΠΡΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ°ΠΊΡΠΎΡΡ, ΡΠ²ΡΠ·Ρ Ρ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·ΠΎΠΌ ΠΈ Π³Π΅ΠΎΠ³ΡΠ°ΡΠΈΠ΅ΠΉ ΡΠ°ΡΡΠ΅ΡΠ½Π½ΠΎΠ³ΠΎ ΡΠΊΠ»Π΅ΡΠΎΠ·Π° // ΠΡΡΠ½. Π½Π΅Π²ΡΠΎΠΏΠ°Ρ, ΠΈ ΠΏΡΠΈΡ ΠΈΠ°ΡΡ, ΠΈΠΌ. Π‘. Π‘. ΠΠΎΡΡΠ°ΠΊΠΎΠ²Π°.- 1992. № 2. — Π‘. 9−12.
- ΠΡΡΠ΅Π² Π.Π., ΠΠ΅ΠΌΠΈΠ½Π° T.J1., ΠΠΎΠΉΠΊΠΎ Π. Π. Π Π°ΡΡΠ΅ΡΠ½Π½ΡΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ·. Π.: ΠΠ΅ΡΡΡ ΠΈ Π³Π°Π·, 1997.-Π‘ 463.
- ΠΠ°Π²Π°Π»ΠΈΡΠΈΠ½ Π.Π. Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΎΠ± ΡΡΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ ΡΠ°ΡΡΠ΅ΡΠ½Π½ΠΎΠ³ΠΎ ΡΠΊΠ»Π΅ΡΠΎΠ·Π° // ΠΡΡΠ½. Π½Π΅Π²ΡΠΎΠΏΠ°Ρ, ΠΈ ΠΏΡΠΈΡ ΠΈΠ°ΡΡ, ΠΈΠΌ. Π‘. Π‘. ΠΠΎΡΡΠ°ΠΊΠΎΠ²Π°. 1990. — № 2.- Π‘. 3−8.
- Π₯ΠΎΠ½Π΄ΠΊΠ°ΡΠΈΠ°Π½ Π.Π., ΠΠ°Π²Π°Π»ΠΈΡΠΈΠ½ Π. Π., ΠΠ΅Π²ΡΠΊΠ°Ρ Π. Π. Π Π°ΡΡΠ΅ΡΠ½Π½ΡΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ·. -Π.: ΠΠ΅Π΄ΠΈΡΠΈΠ½Π°, 1987. Π‘ 256.
- Π¨ΠΌΠΈΠ΄Ρ Π’.Π., Π§ΡΡΠΊΠΈΠ½Π° Π. Π., ΠΠ»Π°Π³ΠΈΠ½Π° Π. Π., Π―Ρ Π½ΠΎ Π. Π. Π’Π΅ΡΠ΅Π½ΠΈΠ΅ ΡΠ΅ΠΌΠΈΡΡΠΈΡΡΡΡΠ΅Π³ΠΎ ΡΠ°ΡΡΠ΅ΡΠ½Π½ΠΎΠ³ΠΎ ΡΠΊΠ»Π΅ΡΠΎΠ·Π° Π½Π° ΡΠΎΠ½Π΅ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΠΎΠΏΠ°ΠΊΡΠΎΠ½ΠΎΠΌ ΠΈ ΠΏΠΎΡΠ»Π΅ Π΅Π³ΠΎ ΠΎΡΠΌΠ΅Π½Ρ // ΠΠ΅Π²ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΆΡΡΠ½Π°Π». 2005. — 10. — № 2. — Π‘. 1−5.
- Adams J.M., Imagawa D.T. Measles antibody in multiple sclerosis // Pros. Soc. Exp. Biol. 1962. — Vol. 111. — P. 562−566.
- Aharoni R., Arnon R., Eilam R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J. Neurosci. 2005- Vol. 25: P 8217−8228.
- Aharoni R., Arnon R., Eilam R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis // J. Neurosci. 2005. — Vol. 25. — P. 8217−8228.
- Aharoni R., Kayhan Π., Eilam R. et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc. Natl. Acad. Sci. USA. 2003- 100: 14 157−14 162.
- Aharoni R., Kayhan Π., Eilam R. et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ // Proc. Natl. Acad. Sci. USA. 2003. — Vol. 100. — P. 14 157−14 162.
- Arnason Π., Bates D. (chairmen) Motivation in multiple sclerosis. -PAREXEL MMS Europe Ltd. 2005. — 55 p.
- Arnason B.G.W., Reder A.T. Interferons and multiple sclerosis // Clin. Neuropharmacol. 1994. — Vol. 17. — P. 495−547.
- Barkhof F., van Waesberghe J.T.M., Filippi M. et al. Ti hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-lb treatment // Brain. 2001. — Vol. 124. — P. 1396−1402.
- Barkhof F., van Waesberghe J-H.T.M., Filippi M. et al. T. hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-lb treatment //Brain. -2001. -Vol. 124.-P. 1396−1402.
- Bayerl C., Bohland P., Jung E.G. Systemic reaction to glatiramer acetate // Contact Dermatitis. 2000. — Vol. 43. — P. 62−63.
- Bernard C.C., Kelerode R.N. Multiple sclerosis: an autoimmune disease of multifactorial etiology // Curr. Opin. Immunol. 1992. — Vol. 4. — P. 760−765.
- Biernacki K., Antel J.P., Blain M. et al. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch. Neurol. 2005- 62 (4): 563−568.
- Biernacki K., Antel J.P., Blain M. et al. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis // Arch. Neurol. 2005. — Vol. 62 (4). — P. 563−568.
- Bornstein M.B., Miller A., Slagle S. et al. A placebo-controlled. Double-blind, randomized, two-center, pilot trial of COP 1 in chronic progressive multiple sclerosis // Neurology. 1991. — Vol. 41. — P. 533−539.
- Borras C. Rio J., Porcel J. et al. Emotional state of patients with relapsing-remitting MS treated with interferon beta-lb // Neurology. 1999. — Vol. 52. -P. 1636−1639.
- Boutros Π’., Croze E., Yong V.W. Interferon-p is a potent promoter of nerve growth factor production by astrocytes. J. Neurochem. 1997- 69: 939−946.
- Boutros Π’., Croze E., Yong V.W. Interferon-p is a potent promoter of nerve growth factor production by astrocytes // J. Neurochem. 1997. — Vol. 69. — P. 939−946.
- Bramanti P., Sessa E., Rifici C. et al. Enhanced spasticity in primary progressive MS patients treated with interferon beta-lb // Neurology. 1998. — Vol. 51. — P. 1720−1723.
- Brenner Π’., Arnon R, Sela M. et al. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone // J. Neuroimmunol. 2001. -Vol. 115.-P. 152−160.
- Brex P.A., Ciccarelli O., O’Riordan J.I. et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis // N. Engl. J. Med. -2002.-Vol. 346 (3).-P. 158−164.
- Brod S.A., Marshall G.D., Henninger E.M. et al. Interferon-(3ib treatment decreases tumor necrosis factor-a and increases interleukin-6 production in multiple sclerosis // Neurology. 1996. — Vol. 46. — P. 1633−1638.
- Brown KA. Factors modifying the migration of lymphocytes across the blood-brain barrier. Int. Immunopharmacol. 2001- 1: 2043−2062.
- Calabresi P.A., Pelfrey C.M., Tranquill L.R. et al. VLA-4 expression on peiypheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta // Neurology. 1997. — Vol. 49. — P. 1111−1116.
- Clanet M., Kappos L., Radue E.W. et al. Results of the European interferon beta la (Avonex) dose-comparision study // J. Neurol. 2001. — Vol. 248 (suppl. 2).-11/63.
- Clanet M., Montalban X. (chairmen). The future of multiple sclerosis therapies. PAREXEL MMS Europe Ltd. 2006: 51 p.
- Clanet M., Montalban X. (chairmen). The future of multiple sclerosis therapies. PAREXEL MMS Europe Ltd. — 2006. — 51 p.
- Cohen J.A., Goodman A.D., Heidenreich F.R. et al. Results of IMPACT, a phase 3 trial of interferon beta-If in secondary progressive MS // Neurology. -2001. Vol. 56 (suppl. 3). — A148-A149.
- Comi G., Moiola L. Copolymer-1 // Baillieres Clin. Neurol. -1997. Vol. 6. -P. 495−509.
- Compston D.A.S., Vakarelis B.N., Paul E. et al. Viral infection in patients with multiple sclerosis and HLA-DR matched controls // Brain. 1986. — Vol. 109. — P. 325−344.
- Coyle P. Results of comparative efficacy trial using two formulations of interferon beta-la in RRMS // J. Neurol. Sci. 2001. — Vol. 187 (suppl. 1). -S436.
- Coyle P.K., Hartung H-P. Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response // Mult. Scler. 2002. — Vol. 8. — P. 2−9.
- Dayal A.S., Jensen M.A., Lledo A., Arnason B.G.W. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-lb // Neurology. 1995.-Vol. 45.-P. 2173−2177.
- Dhib-Jalbut S. Glatiramer acetate (Copaxone®) therapy for multiple sclerosis // Pharmacol. Therapeutics. 2003. — Vol. 98. — P. 245−255.
- Dhib-Jalbut S. Glatiramer acetate (Copaxone®) therapy for multiple sclerosis // Pharmacol. Ther. 2003. — Vol. 98. — P. 245−255.
- Dong C, Flavell RA. Cell fate decision: T-helper 1 and 2 subsets in immune responses. Arthritis Res. 2000- 2: 179−188.
- Drago F., Brusati C., mancardi G. Et al. Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis // Arch. Dermatol. 1999. — Vol. 135. — P. 1277−1278.
- Duda P.W., Schmied M.C., Cook S.L. et al. Glatiramer acetate (Copaxone) induces degenerate, Th2-porarized immune responses in patients with multiple sclerosis // J. Clin. Invest. 2000. — Vol. 105. — P. 967−976.
- Ebers G., Traboulsee A., Li D. et al. Final results from the interferon beta-lb 16-year long-term follow-up study // Mult. Scler. 2006. — Vol. 12., Suppl. 1. -S. 189 (P666).
- Ebers G.C., Sadovnick A.D. Susceptibility: genetic in multiple sclerosis // Multiple sclerosis. Eds. Paty D.W., Ebers G.C. F.A.Davis Company, Philadelphia, 1998. — P. 29−47.
- Elgart G.W., Sheremata W., Ahn Y.S. Cutaneous reactions to recombinant human interferon beta-lb: the clinical and histologic spectrum // J. Am. Acad. Dermatol. 1997. — Vol. 37. — P. 254−258.
- European Study Group on Interferon f3-lb in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon f3-lb in treatment of secondary progressive multiple sclerosis // Lancet. 1998. — Vol. 352. — P. 1491−1497.
- Feinstein A., O’Connor P., Feinstein K. Multiple sclerosis, interferon beta-lb and depression. A prospective investigation // J. Neurol. 2002. — Vol. 249 (7).-P. 815−820.
- Filippi M., Bozzali M., Rovaris M. et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain. 2003- 126: 433−437.
- Filippi M., Rovaris M., Rocca M.M. et al. European/Canadian Glatiramer Acetate Study Group. Glatiramer acetate reduces the proportion of new MS lesions evolving into «black holes». Neurology. 2001- 57: 731−733.
- Filippi M., Rovaris M., Rocca M.M. et al. European/Canadian Glatiramer Acetate Study Group. Glatiramer acetate reduces the proportion of new MS lesions evolving into «black holes» // Neurology. 2001. Vol. 57. — P. 731 733.
- Flechter S., Vardi J., Pollak L., Rabey J.M. Comparison of glatiramer acetate (Copaxone) and interferon beta-lb (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up // J. Neurol. Sci. 2002. — Vol. 197 (1−2). — P. 51−55.
- Fletcher S., Vardi J., Pollak L., Rabey J.M. Comparison of glatiramer acetate (Copaxone) and interferon beta-lb (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up 11 J/ Neurol. Sci. 2002. — Vol. 197 (1−2). — P. 51−55.
- Ford C.C., Johnson K.P., Lisak R.P. et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients // Mult. Scler. 2006. — Vol. 12 (3). — P. 309−320.
- Francis D.A., Thompson A.J., Brookes P. et al. Multiple sclerosis and HLA: is the susceptibility gene really HLA-DR or DQ? // Hum. Immunology. -1991.-Vol. 32.-P. 119−124.
- Freedman M.S., Blumhardt L.D., Brochet B. et al. International consensus stetment on the use of disease-modifying agents in multiple sclerosis // Mult. Scler. 2002. — Vol. 8. — P. 19−23.
- Gaines A.R., Varricchio F. Interferon beta-lb injection site reactions and necroses // Mult. Scler. 1998. — Vol. 4. — P. 70−73.
- Giovannoni G., Goodman A. Neutralizing anti-IFN-P antibodies, How much more evidence do we need to use them in practice? // Neurology. 2005. -Vol. 65.-P. 6−8.
- Goeb J.L., Cailleau A., Laine P. et al. Acute dellirium, delusion, and depression during IFN-bata-la therapy for multiple sclerosis: a case report // Clin. Neuropharmacol. 2003. — Vol. 26 (1). — P. 5−7.
- Goodin D.S. Interferon-|3 therapy in multiple sclerosis. Evidence for clinically relevant dose response // Drugs. 2001. — Vol. 61 (12). — P. 1693−1703.
- Goodin D.S., Frohman E.M., Garmany G.P. et al. Disease modifying therapies in multiple sclerosis // Neurology. 2002. — Vol. 58. — P. 169−178.
- Goodkin D.E., North American Study Group. Interferon beta-lb in secondary progressive MS: clinical and MRI results of a 3-year randomised controlled trial // Neurology. 2000. — Vol. 54. — P. 2352.
- Haas J., Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone) // Eur. J. Neuro. — 2005. -Vol. 12 (6).-P. 425−431.
- Hemmer Π., Archelos J.J., Hartung H-P. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 2002- 3: 291 301.
- Hillert J. Human leukocyte antigen studies in multiple sclerosis // Ann Neurology. 1994. — Vol. 36. — P. 15−17.
- Hillert J., Gronning M., Nyland H. An immunogenetic heterogeneity in multiple sclerosis // J. Neurol. Neurosurg. Psychiatr. 1992. — Vol. 55. — P. 887−890.
- Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives Invited review. Brain. 1997- 120: 865−916.
- Holliday S.M., Benfield P. Interferon-P-la. A review of its pharmacological properties and therapeutic potential in multiple sclerosis // BioDrugs. 1997. -Vol. 8 (4).-P. 317−330.
- Iarlori C., Reale M., Lugaresi A. Et al. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with inerferon-beta lb // J. Neuroimmunol, 2000. — Vol. 107. — P. 100−107.
- Jacobs L.D., Cookfair D.L., Rudick R.A. et al. Intramuscular interferon beta-1 a for disease progression in exacerbating-remitting multiple sclerosis // Ann. Neurol. 1996. — Vol. 39.- P. 285−294.
- Johnson K.P., Brooks B.R., Cohen J.A. et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect onmultiple sclerosis relapse rate and degree of disability // Neurology. 1998. -Vol. 50.-P. 701−708.
- Johnson K.P., Brooks B.R., Ford C.C. et al., and the Copolymer 1 Multiple Sclerosis Study Group. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years// Mult. Scler. 2000. -Vol. 6.-P. 255−266.
- Johnson K.P., Calabresi P.A. Interferon-(3-lb: prophylactic therapy in multiple sclerosis. Handbook of multiple sclerosis. Ed. S.D.Cook. 3nd ed. Marcel Dekker Inc. 2001: 503−518.
- Johnson K.P., Calabresi P.A. Interferon-(3-lb: prophylactic therapy in multiple sclerosis // Handbook of multiple sclerosis. Ed. S.D.Cook. 3nd ed. -Marcel Dekker Inc. 2001. — P. 503−518.
- Kappos L., Traboulsee A., Constantinescu C. et al. Long-term subcutaneous interferon beta-la therapy in patients with relapsing-remitting MS // Neurology. 2006. — Vol. 67 (6). — P. 930−931.
- Karandikar N.J." Crawford M.P., Yan X. et al. Glatiramer acetate (Copaxone) therapy induced CD8+ T cell responses in patients with multiple sclerosis // J. Clin. Invest. 2002. — Vol. 109. — P. 641−649.
- Kesselring J., Lassmann H. Pathogenesis // Multiple sclerosis. Ed. Kesselring J. -Cambridge University Press, 1997. P. 54−62.
- Khan O.A., Hebel J.R. Incidence of exacerbations in the first 90 days of treatment with recombinant human interferon (3-lb in patients with relapsing-remitting multiple sclerosis // Ann. Neurol. 1998. — Vol. 44. — P. 138−139.
- Klapper J.A. Interferon beta treatment of multiple sclerosis // neurology. -1994.-Vol. 44.-P. 188.
- Knobler R.L., Kelley C.L., Trantas F. et al. Interferon beta-lb induced ulcerative skin lesions in MS // J. Neuroimmunol. 1994. — Vol. 54. — P. 173. Abstract.
- Korczyn A.D., Nisipeanu P. Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel // J. Neurol. 1996. -Vo. 243, suppl. l.-S 23−26.
- Korczyn A.D., Nisipeanu P. Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel // J. Neurol. 1996. -Vo. 243, suppl. l.-S 23−26.
- Kurtzke J.F. Epidemiologic contribution of multiple sclerosis: an overview // Neurology. 1980. — Vol. 30 (2). — P. 61−79.
- Kurtzke J.F. Neurologic impairment in multiple sclerosis and the disability status scale // Acta Neurol. Scand. 1970. — Vol. 46. — P. 493−512.
- Leppert D., Waubant E., Burk M.R. et al. Interferon beta-lb inhibits gelatinase secretion and in vivo migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis // Ann. Neurol. 1996. -Vol. 40.-P. 846−852.
- Li D.K.B., Zhao G.J., Paty D.W. et al. Randomized controlled trial of interferon-beta-la in secondary progressive MS. MRI results // Neurology. -2001.-Vol. 56.-P. 1505−1513.
- Liu Π‘., Blumhardt L.D. Randomized, double-blind, placebo-controlled study of subcutaneous interferon beta-la in relapsing-remitting multiple sclerosis: a categorical disability trend analysis // Mult. Scler. 2002. — Vol. 8. — P. 10−14.
- Lobel E., Riven-Krietman R., Amselem A. et al. Copolymer 1 // Drug Fut. -1996.-Vol. 21.-P. 131−134.
- Lublin F.D., Whitaker J.N., Eidelman B.H. et al. Management of patients receiving interferon beta-lb for multiple sclerosis: report of a consensus conference // Neurology. 1996. — Vol. 46. — P. 12−18.
- Mancardi G.L., Murialdo A., Drago F. et al. Localized lipoatrophy after prolonged treatment with copolymer 1 // J. Neurol. 2000. — Vol. 247. — P. 220−221.
- Miller A., Shapiro S., Gershtein R. et al. Treatment of multiple sclerosis with Copolymer-1 (Copaxone®): implicating mechanisms of Thl to Th2/Th3 immune-deviation // J. Neuroimmunol. 1998. — Vol. 92. — P. 113−121.
- Milo R., Panitch H. Glatiramer acetate or Interferon-P for multiple sclerisis? A guide to drug choice // CNS Drugs. 1999. — Vol. 11 (4). — P. 289−306.
- Munafo A., Trinchard-Lugan I., Nguyen T.X.Q., Buraglio M. Comparative Pharmicokinetics and pharmicodynamics of recombinant human interferon beta la after intramuscular and subcutaneous administration // Eur. J. Neurol. 1998. — Vol. 5. — P. 1−7.
- Neuhaus O., Archelos J.J., Hartung H-P. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. TRENDS Pharmacol. Sci. 2003- 24 (3): 131−138.
- Neuhaus O., Farina C., Wekerle H., Hohlfeld R. Mechanism of action of glatiramer acetate in multiple sclerosis. Neurology. 2001- 56: 702−708.
- Noronha A., Toscas A., Jensen M.A. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis // J. Neuroimmunol. 1993. — Vol. 46. — P. 145−153.
- Noseworthy J.H. Treatment of multiple sclerosis and related disorders: what’s new in the past 2 years? // Clin. Neurpoharmacol. 2003. — Vol. 26. -P. 28−37.
- O’Riordan J.I., Thompson A.J., Kingsley D.P. et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up // Brain. 1998. — Vol. 121. — P. 495−503.
- Ozenci V., Kouwenhoven M., Teleshova N. Et al. Multiple sclerosis: pro-and antiinflammatory cytokines and metalloproteinases and affected differentially by treatment with interferon-beta // J. Neuroimmunol. 2000. -Vol. 108.-P. 236−243.
- Panitch H. Prophylactic therapy glatiramer acetate (Copaxone) // Handbook of multiple sclerosis. Ed. S.D.Cook. 3nd ed. — Marcel Dekker Inc. -2001.-P. 541−560.
- Panitch H. Prophylactic therapy glatiramer acetate (Copaxone). Handbook of multiple sclerosis. Ed. S.D.Cook. 3nd ed. Marcel Dekker Inc. 2001: 541−560.
- Panitch H., Goodin D.S., Francis G. et al. Randomized, comparative study of interferon (3−1 a treatment regimens in MS. The EVIDENCE trial // Neurology. -2002. Vol. 59. — P. 1496−1506.
- Panitch H.S. Influence of interferon on exacerbation of multiple sclerosis // Ann. Neurology. 1994. — Vol. 36, suppl. — P. 26−28.
- Paten S.B., Metz L.M. Interferon (3−1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial // Mult. Scler. 2001. — Vol. 7. — P. 243−248.
- Paten S.B., Metz L.M. Interferon (3-la and depression in secondary progressive MS: data from the SPECTRIMS trial // Neurology. 2002. — Vol. 59.-P. 746.
- Patten S.B. What is the best approach to treating interferon-induced depression in people with multiple sclerosis? // J. Psych. Neurosc. 2001. -Vol. 26. — P. 66.
- Patten S.B., Fridhandler S., Beck C.A., Luanne M.M. Depressive symptoms in a treated multiple sclerosis cohort // Multiple Sclerosis. 2003. -Vol. 9.-P. 616−620.
- Perron H. MSRV retrovirus and gliotoxin protein: potential biological markers in multiple sclerosis? // Ann. Biol. Clin. 1998. — Vol. 56 (4). — P. 427−438.
- Perumal J., Filippi M., Ford C. Glatiramer acetate therapy for multiple sclerosis: a review // Expert. Opin. Drug. Metab. Toxicol. 2006. — Vol. 2(6). -P. 1019−1029.
- Poser C.M. Pathogenesis of multiple sclerosis // Acta. Neuropathol. 1986. -Vol. 71. — P. 1−10.
- PRISMS Study Group, UBC MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-la in relapsing MS // Neurology. 2001. -Vol. 56.-P. 1628−1636.
- PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon 0−1 a in relapsing-remitting multiple sclerosis // Lancet.1998. Vol. 352. — P. 1498−1504.
- Rieger-Ziegler V., Kranke Π., Soyer P., Aberer W. Large cutaneous-subcutaneous infiltrates: a side effect of interferon beta injections // Hautarzt. -1998.-Vol. 49.-P. 310−312.
- Riise Π’., Wolfson C. The epidemiologic study of exogenous factors in the etiology of multiple sclerosis // Neurology. 1997. — Vol. 49, № 2, Suppl. 2 -82 p.
- Rio J Porcel J., Tellez N., Sanchez-Betancourt A. Et al. Factors related with treatment adherence to interferon beta and glatiramer acetate in multiple sclerosis // Mult. Scler. 2005. — Vol. 11. — P. 306−309.
- Rudick R.A., Goodkin D.E., Jacobs L.D. et al. Impact of interferon beta-la on neurological disability in relapsing multiple sclerosis // Neurology.1997.-Vol. 49.-P. 358−363.
- Rudick R.A., Ransohoff R.M., Lee J.-C. Et al. In vivo effects of interferon beta-la on immunosuppressive cytokines in multiple sclerosis // Neurology.1998. Vol. 50. — P. 1294−1300.
- Salmon P., Le Cotonnee J.Y., Galazka A. Et al. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers // J. Interferon Cytokine Res. 1996. — Vol. 16. — P. 759−764.
- Sela M., Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis // Expert. Opin. Pharmacother. 2001. — Vol. 2. — P. 1149−1165.
- Sharief M.K. Dose and frequency of administration of interferon-P affect its efficacy in multiple sclerosis // Clin. Drug Invest. 2003. — Vol. 23 (9). — P. 551−559.
- Sharief M.K., Semra Y.K., Seidi O.A., Zoukos Y. Interferon-beta therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis // J. Neuroimmunol. 2001. — Vol. 120. — P. 199−207.
- Simon J.H., Jacobs L.D., Campion M. et al. Magnetic resonance studies of intramuscular interferon P-la for relapsing multiple sclerosis // Ann. Neurol. 1998. — Vol. 43. — P. 79−87.
- Sorensen P. S., Deisenhammer F., Duda P. Et al. Guidelines on use of anti-IFN-P antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-P antibodies in multiple sclerosis // Europ. J. Neurol. 2005. -Vol. 12.-P. 817−827.
- SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-la in secondary progressive MS. Clinical results // Neurology. 2001. -Vol. 56.-P. 1496−1504.
- Steinman L. Multiple sclerosis: a two-stage disease. Natl. Immunol. 2001- 2: 762−764.
- Sturzebecher S., Maibauer R., Heuner A. Et al. Pharmacodynamic comparision of single doses of IFNpia and IFNpib in healthy volunteers // J. Interferon Cytokine Res. 1999. — Vol. 19. — P. 1257−1264.
- Stuve O., Dooley N.P., Uhm J.H. et al. Interferon-P decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9 // Ann. Neurol. 1996. — Vol. 40. — P. 853−863.
- The IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicentral, randomized double bind, placebo-controlled trial. Neurology. 1993- 43: 655−661.
- The Π WINS Study Group. Evidence of interferon P-la dose response in relapsing-remitting MS. The OWINS Study // Neurology. 1999. — Vol. 53. -P. 679−686.
- Trapp B.D., Ransohoff R.M., Fisher E., Rudick R.A. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist. 1999−5:48−57.
- Trojano M., Avolio Π‘., Liuzzi G.M. et al. Changes of serum sICAM-1 and MMP-9 induced by interferon-beta lb treatment in relapsing-remitting MS // Neurology. 1999. — Vol. 53. — P. 1402−1408.
- Van Rengen A., Goossens A. Local reactions after subcutaneous injections of P-interferon // Contact Dermatitis. 1997. — Vol. 39. — P. 209.
- Vartanian T. An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis // Clin. Ther. 2003. — Vol. 25(1). — P. 105−118.
- Venken K., Hellings N., Hensen K. et al. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. J. Neurosci. Res. 2006- 83 (8): 1432−1446.
- Walter E.U., Hohlfeld R. Multiple sclerosis. Side effects of interferon beta therapy and their management // Neurology. 1999. — Vol. 53. — P. 16 221 627.
- Walther E.U., Hohlfeld R. Multiple sclerosis. Side effects of interferon beta therapy and their management // Neurology. 1999. — Vol. 53. — P. 16 221 627.
- Weinberg J.M., Wolfe J.T., Sood S. et al. Cutaneous necrosis associated wiyh recombinant interferon injection. Report of three cases with interferon beta-lb and review of the literature // Acta Derm. Venerol. (stockh.). 1997. — Vol. 77. — P. 146−148.
- Weinshenker B.G., Bass Π., Rice G.P. et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course // Brain. 1989. — Vol. 112. — P. 1419−1428.
- Yong V.W. Differential mechanisms of action of interferon-P and glatiramer acetate in MS. Neurology. 2002- 59: 802−808.
- Yong V.W. Differential mechanisms of action of interferon-P and glatiramer acetate in MS // Neurology. 2002. — Vol. 59. — P. 802−808.
- Yong V.W., Chabot S., Stuve O., Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology. 1998- 51: 682−689.
- Yong V.W., Chabot S., Stuve O., Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action // Neurology. 1998. -Vol. 51.-P. 682−689.
- Zang Y.C., Haider J.B., Samanta A.K. et al. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1 alpha by interferon-beta // J. Neuroimmunol. 2001. — Vol. 112. — P. 174−180.
- Ziemssen Π’., Neuhaus O., Hohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis // Drug Safety. 2001. — Vol. 24 (13). — P. 979 990.
- Ziemssen Π’., Neuhaus O., Hohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis // Drug Safety. 2001. — Vol. 24 (13). — P. 979 990.
- Zvartau-Hind M., Caon C., Zabad R. Et al. Glatiramer acetate for multiple sclerosis: a comprehensive review of mechanisms and clinical efficacy // Exp. Rev. Neurotherapeutics. 2002. — Vol. 2 (3). — P. 285−294.